Advertisement


Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

2015 ASCO Annual Meeting

Advertisement

Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).



Related Videos

Skin Cancer

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Lymphoma

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Prostate Cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).

Global Cancer Care
Cost of Care

John Smyth, MD, on The Current State of Cancer Research and Treatment: The European Perspective

John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.

Head and Neck Cancer

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).

Advertisement

Advertisement




Advertisement